Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported first-quarter 2026 financial results on Monday, emphasizing the growing commercial momentum of TONMYA, its recently approved fibromyalgia treatment, and progress across its clinical pipeline. TONMYA, the first new fibromyalgia medicine in 15 years, has shown increases in prescriptions, prescribers, refills and patient access since its launch in November 2025. A recently announced managed care agreement is expected to expand potential coverage to approximately 35 million U.S. commercial lives, a significant step in broadening patient access.
The company’s pipeline also advanced with positive Phase 1 data for TNX-4800, a monoclonal antibody candidate for Lyme disease prophylaxis. Tonix plans to initiate a Phase 2 study of TONMYA in major depressive disorder later this year, exploring the drug's potential beyond fibromyalgia. The company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease, and its immunology pipeline features TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the company’s flagship medicine. Tonix’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
The latest news and updates relating to TNXP are available in the company’s newsroom at https://ibn.fm/TNXP. For the full press release, visit https://ibn.fm/oVPHY.
